Skip to main content
Top
Published in: Drug Safety 3/2007

01-03-2007 | Leading Article

Psychiatric Adverse Reactions with Statins, Fibrates and Ezetimibe

Implications for the Use of Lipid-Lowering Agents

Authors: Dr Michael Tatley, Ruth Savage

Published in: Drug Safety | Issue 3/2007

Login to get access

Abstract

The HMG-CoA reductase inhibitors (‘statins’) have come into widespread use internationally. There has been a long history of their use in New Zealand and this use has increased in recent years. There has also been an increase in the number of reports to the New Zealand Centre for Adverse Reactions Monitoring (CARM) of suspected psychiatric adverse reactions associated with statins. The reactions mentioned in these reports include depression, memory loss, confusion and aggressive reactions. Convincing reports to CARM of recurrence of these reactions upon rechallenge add weight to recent studies reporting serious psychiatric disturbances in association with statin treatment. Aggressive reactions associated with statins are poorly documented in the literature. These observations emphasise the need to be vigilant in looking for these reactions as they can have a significant personal impact on a patient. The observation that other lipid-lowering agents have similar adverse effects supports the hypothesis that decreased brain cell membrane cholesterol may be important in the aetiology of these psychiatric reactions.
Literature
1.
go back to reference Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997 Jul 23-30; 278(4): 313–21PubMedCrossRef Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997 Jul 23-30; 278(4): 313–21PubMedCrossRef
2.
go back to reference Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998 Jan 15; 128(2): 89–95PubMed Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998 Jan 15; 128(2): 89–95PubMed
3.
go back to reference Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001 Jun; 21(6): 767–9PubMedCrossRef Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001 Jun; 21(6): 767–9PubMedCrossRef
4.
go back to reference Scott HD, Laake K. Statins for the reduction of risk of Alzheimer’s disease. Cochrane Database Syst Rev 2001 (3): CD003160PubMed Scott HD, Laake K. Statins for the reduction of risk of Alzheimer’s disease. Cochrane Database Syst Rev 2001 (3): CD003160PubMed
5.
go back to reference Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004 Apr; 97(4): 229–35PubMedCrossRef Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004 Apr; 97(4): 229–35PubMedCrossRef
6.
go back to reference Simons J. The $10 billion pill. Fortune. 2003 Jan 20; 147(1): 58–62PubMed Simons J. The $10 billion pill. Fortune. 2003 Jan 20; 147(1): 58–62PubMed
7.
go back to reference Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001; 61(2): 197–206PubMedCrossRef Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001; 61(2): 197–206PubMedCrossRef
8.
go back to reference Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001 Aug 18; 323(7309): 359CrossRef Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001 Aug 18; 323(7309): 359CrossRef
9.
go back to reference Savage R, Tatley M. Myopathy with statins: check CK levels and interactions. Prescriber Update 2004 May; 25(1): 4–5 Savage R, Tatley M. Myopathy with statins: check CK levels and interactions. Prescriber Update 2004 May; 25(1): 4–5
10.
go back to reference Golomb BA, Criqui MH, White H, et al. Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004 Jan 26; 164(2): 153–62PubMedCrossRef Golomb BA, Criqui MH, White H, et al. Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004 Jan 26; 164(2): 153–62PubMedCrossRef
11.
go back to reference Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002 May 14; 58(9): 1333–7PubMedCrossRef Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002 May 14; 58(9): 1333–7PubMedCrossRef
12.
go back to reference Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003 Jul; 23(7): 871–80PubMedCrossRef Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003 Jul; 23(7): 871–80PubMedCrossRef
13.
go back to reference King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003 Dec; 23(12): 1663–7PubMedCrossRef King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003 Dec; 23(12): 1663–7PubMedCrossRef
14.
go back to reference Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemia adults. Am J Med 2004 Dec 1; 117(11): 823–9PubMedCrossRef Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemia adults. Am J Med 2004 Dec 1; 117(11): 823–9PubMedCrossRef
15.
go back to reference Manfredini R, Caracciolo S, Salmi R, et al. The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link. J Int Med Res 2000 Nov-Dec; 28(6): 247–57PubMed Manfredini R, Caracciolo S, Salmi R, et al. The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link. J Int Med Res 2000 Nov-Dec; 28(6): 247–57PubMed
16.
go back to reference Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005 Feb 28; 133(2-3): 197–203PubMedCrossRef Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005 Feb 28; 133(2-3): 197–203PubMedCrossRef
17.
go back to reference Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime. J Psychiatr Res 2000 Jul-Oct; 34(4-5): 301–9PubMedCrossRef Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime. J Psychiatr Res 2000 Jul-Oct; 34(4-5): 301–9PubMedCrossRef
18.
go back to reference Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med 1998 Mar 15; 128(6): 478–87PubMed Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med 1998 Mar 15; 128(6): 478–87PubMed
19.
go back to reference Saheki A, Terasaki T, Tamai I, et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994 Feb; 11(2): 305–11PubMedCrossRef Saheki A, Terasaki T, Tamai I, et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994 Feb; 11(2): 305–11PubMedCrossRef
21.
go back to reference Wardle J, Rogers P, Judd P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med 2000 May; 108(7): 547–53PubMedCrossRef Wardle J, Rogers P, Judd P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med 2000 May; 108(7): 547–53PubMedCrossRef
Metadata
Title
Psychiatric Adverse Reactions with Statins, Fibrates and Ezetimibe
Implications for the Use of Lipid-Lowering Agents
Authors
Dr Michael Tatley
Ruth Savage
Publication date
01-03-2007
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730030-00003

Other articles of this Issue 3/2007

Drug Safety 3/2007 Go to the issue

Special Article

The Erice Manifesto